Miralax Dispensing Quantity
Order a 30-day supply, which equals 30 packets of 17 grams each (510 grams total), as the standard initial dose is 17 g once daily. 1
Standard Dosing
The 2023 AGA-ACG clinical practice guideline establishes 17 g daily as the recommended initial dose for polyethylene glycol 3350 (Miralax) in chronic idiopathic constipation 1. This dosing is:
- FDA-approved for occasional constipation at 17 g daily 1
- Supported by moderate-quality evidence showing efficacy for up to 6 months 1
- Demonstrated safe and effective for up to 12 months in open-label studies 2
Practical Dispensing Considerations
Initial Supply
- Start with 30 packets (17 g each) for a one-month trial
- This allows assessment of response before committing to larger quantities
- Commercial packaging includes 10-packet and 20-packet boxes 3
Dose Titration
The guidelines specify "per symptom response and side effects" with no clear maximum dose 1. This means:
- If inadequate response after 1-2 weeks, the dose can be increased
- Some patients may require higher doses (studies used up to 17.5 g twice daily) 1
- Titration should be gradual to minimize GI side effects
Long-term Management
For patients requiring chronic therapy:
- Order 90-day supplies (90 packets) once efficacy is established 2
- Response has been shown to be durable over 6 months without tachyphylaxis 1, 2
- Monthly cost ranges from $10-$45, making larger supplies cost-effective 1
Common Pitfalls to Avoid
Don't underdose: The evidence-based dose is specifically 17 g daily, not "a capful" or vague instructions. Each packet contains exactly 17 g 3.
Don't limit to short-term only: While FDA-approved for "occasional" constipation, clinical trials demonstrate safety and efficacy for chronic use up to 12 months 2, and guidelines support long-term use 1.
Ensure adequate hydration: Each 17 g dose should be mixed in 8 ounces (237 mL) of liquid 1, 4. Inadequate fluid intake reduces efficacy.
Side Effect Profile
Common adverse effects are mild and transient 1:
- Bloating, flatulence, abdominal discomfort
- Diarrhea (158 more per 1,000 vs placebo) 1
- Most GI adverse events decrease markedly after the first week 5
Safety note: No clinically significant electrolyte disturbances occur with chronic use, even in elderly patients 2. Serious adverse events are rare (RR 0.47, CI 0.16-1.33) 1.